Effectiveness of Natalizumab in Achieving No Evidence of Disease Activity (NEDA-3) —Data From a Local Norwegian Cohort
Conclusion: Despite the high rate of treatment switch, mainly due to the risk of PML, almost one in four who started on NTZ achieved NEDA-3 after 5 years, and the overall disease progression was low in the total cohort. Treating less advanced disease seems to predict better long-term stability.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Brain | Disability | Multiple Sclerosis | Neurology | Norway Health | Pregnancy | Study | Transplants | Tysabri | Women